case_images: PMC10827299_01
case_images: An endoscopic view prior to head and neck photoimmunotherapy (HN-PIT).
case_images: cro-2024-0017-0001-536166_F01.jpg
case_images: PMC10827299_01_cro-2024-0017-0001-536166_F01.jpg
case_images: F1
case_images: The target lesion was located in the lateral to posterior wall of the mesopharynx, adjacent to the reconstructed skin valve, and measured 33 mm x 22 mm (shown in Fig. 1).
case_images: CT images of disease progression after HN-PIT.
case_images: cro-2024-0017-0001-536166_F02.jpg
case_images: PMC10827299_01_cro-2024-0017-0001-536166_F02.jpg
case_images: F2
case_images: In October 2022, 6 months after the first cycle of HN-PIT, CT findings showed that the tumor had grown in the direction of the nasopharynx and masticatory muscle space and was considered progressive disease (shown in Fig. 2).
case_images: a Computed tomography (CT) images 2 months after the first dose of pembrolizumab. b CT scan images 1 year after the first dose of pembrolizumab.
case_images: cro-2024-0017-0001-536166_F03.jpg
case_images: PMC10827299_01_cro-2024-0017-0001-536166_F03.jpg
case_images: F3
case_images: Two months after the first dose of pembrolizumab, the recurrent lesions were no longer visible on CT scan (shown in Fig. 3a). Currently, in October 2023, more than 1 year after starting pembrolizumab, there has been no local recurrence (shown in Fig. 3b), and the patient continues to receive pembrolizumab.